PARP Inhibitor Drugs Found to Have Hidden Talent

Designed to subvert tumor cells from within, a growing number of cancer drugs have also been found to have other talents. In the last few years, scientists have discovered that targeted drugs known as CDK4/6 inhibitors and certain chemotherapy agents not only hamper the internal workings of cancer cells but can also make them the … Continued

Dana-Farber Experts Aid Ambitious Projects One Cell at a Time

Like ambitious cartographers bent on mapping entire countries down to their individual houses, scientists are using state-of-the-art methods to create two mammoth atlases — one aimed at mapping human cells of every type, and the other a 3D atlas of every molecular feature of cancer as it develops, spreads, and responds to treatment. The Human … Continued

Crowdsourcing Yields AI-Based Tool to Improve Radiation Therapy in Lung Cancer

Crowdsourcing is an increasingly powerful approach for fueling innovation in many sectors but has not been routinely applied in academic medicine. Scientists at Dana-Farber/Harvard Cancer Center are exploring ways to harness this method for solutions to pressing clinical problems, such as the worldwide shortage of radiation oncologists. Their work has led to the development of … Continued

New Drug Target Found in Subset of Metastatic Prostate Cancers

Medically reviewed by Himisha Beltran, MD Prostate cancer, when diagnosed early, can be a very treatable disease. Even advanced prostate cancer has treatment options. But some advanced, metastatic prostate cancers become resistant to standard therapies by shapeshifting into a different type of cancer, called small cell neuroendocrine prostate cancer. These neuroendocrine tumors tend to be … Continued

Scientists Identify Pathway Driving Natural Killer Cell Activity

Medically reviewed by Laurie H. Glimcher, MD, and Rizwan Romee, MD Immune cells called natural killer (NK) cells are a key arm of the body’s defenses against infections and cancers, but what provokes them into action is less well understood than some other immune components such as T cells. “Critical gaps in our knowledge regarding … Continued

How are bispecific antibodies being used to treat blood cancers?

Many of the immunotherapy drugs that are transforming the treatment of certain types of cancer are based on antibodies — artificial proteins that latch onto a molecular target, called an antigen. Bispecific antibodies, which can bind to two antigens at the same time, are being tested and moving toward clinical use in some blood cancers. … Continued

With precision cancer medicine, a success against endometrial cancer

In the annals of patients who have benefited from Dana-Farber and Brigham and Women’s Hospital’s (BWH) genomic sequencing program Profile, few involve a turnabout as dramatic as one recently reported in Gynecologic Oncology. Authored by nearly a dozen Dana-Farber and BWH faculty, the paper recounts the medical history of a 49-year-old Nebraska woman first diagnosed … Continued

New study uncovers strategy for defusing castration-resistant prostate cancer

Cancer is often fueled by hormones, including the male sex hormone testosterone, which spur tumor growth in most forms of prostate cancer. Doctors can defuse this destructive relationship, typically with drugs (or sometimes surgery), but frequently, the tumors adapt or evolve, devising ways to incite cancer growth even in the absence of hormone-driven signals. These … Continued

Study Uncovers Dual Gene-Control System in Multiple Myeloma

The process of converting genetic information from DNA to RNA, known as transcription, is a joint undertaking. Sections of DNA, known as promoters, collaborate with other sections known as enhancers to recast the genetic code into a form that can be used by cells to make proteins. As with many partnerships, however, it hasn’t been … Continued

“Active Loading” Technology Speeds up Single Cell Drug Testing Devices

High-tech devices that flow cancer cells over a miniaturized “scale” to measure changes in the weight of single living cells are increasingly being used to test the susceptibility of cancer cells to different drugs. The devices are so sensitive that they can measure a change in growth rate of a cell within hours or days … Continued

Exceptional Immunotherapy Response Triggers Search for the Cause

Six years’ worth of repeated surgeries, radiation, and chemotherapy with three different agents failed to halt the growth of Frances Zichichi’s brain tumor. As it kept recurring and more surgeries were required, Zichichi lost the use of her left side. Eventually the cancer formed masses under her scalp, causing pain, which was dulled only with … Continued

CRISPR-Cas9 Screen Opens New Targets for Ewing Sarcoma, Other Childhood Cancers

This post originally appeared on Vector, Boston Children’s Hospital’s blog. While the genetic mutations driving adult cancers can sometimes be targeted with drugs, most pediatric cancers lack good targets. That’s because their driving genetic alterations often create fusion proteins that aren’t easy for drugs to attack. “This is one reason why it is notoriously hard … Continued

Targeting Tumor Heterogeneity To Reduce Treatment Resistance

One of the biggest challenges in treating cancer is that the cells making up a tumor – say a breast or lung tumor – are enormously diverse, or heterogeneous. This tumor heterogeneity can be both genetic, meaning the DNA in the tumor cells differs from one cell to the next, and epigenetic, meaning that the … Continued

Personalizing Treatment: The Latest in Breast Cancer Research

One of the primary goals of breast cancer research is to personalize the treatment of the disease, tailoring therapies to the specific characteristics of each patient’s cancer.  “The future of breast cancer therapy is tied to the idea of individualizing treatment for each patient—not only to the stage and subtype of the cancer but also … Continued

Myeloma Study Makes the Case for a New Standard for Predicting Long-Term Outcome

As new treatments for multiple myeloma have extended patient survival—from an average of three years to more than 10 in some cases—physicians and researchers face a new challenge: how to predict a drug’s long-term effectiveness? How to tell, early on, whether one drug is likely to extend patients’ lives more than another? At Dana-Farber’s Jerome Lipper … Continued

Trials Open New Avenues of Endometrial Cancer Treatment

In recent years, there has been a dearth of clinical trials studying new approaches to how endometrial cancer, which forms in the lining of the uterus, is treated. That is changing rapidly, however, as basic research into the disease spurs the testing of novel drugs and drug combinations. A host of clinical trials—including four led … Continued

Research Update: Scientists Present Novel Ways of Treating Blood Cancers and Diseases

Dana-Farber scientists presented an abundance of new research at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 1-4 in San Diego. Their research spanned the gamut of hematological diseases, including leukemia, lymphoma, multiple myeloma, and myelodysplastic syndrome—as well as treatment modalities, such as stem cell transplantation and CAR T-cell therapy. A … Continued

ctDNA: Bringing ‘liquid biopsies’ to pediatric solid tumors

This post originally appeared on Vector, Boston Children’s Hospital’s blog. Our blood carries tiny amounts of DNA from broken-up cells. If we have cancer, some of that DNA comes from tumor cells. Studies performed with adult cancers have shown that this circulating tumor DNA (ctDNA) may offer crucial clues about tumor genetic mutations and how … Continued